Patents

The Cardea Patent Portfolio.

Cardea has since 2013 been the R&D pioneer of graphene transistors and biosensors for detection of biological signals. Cardea is today the only company in the world with IP and a capability to mass produce – at scale and at commercial viable quality – gFETs (Graphene Field Effect Transistors), also known as graphene biosensors.

 

As of October 5, 2020

Owned 19 Granted Patents
  • 17 granted patents in the US
  • 1 granted patents in the EP
  • 1 granted patent in Japan
Pending 20 Owned Patent Applications
  • 2 applications allowed in the US
  • 1 application allowed in the EU
  • 5 applications pending in the US
  • 4 applications pending in the EU
  • 3 applications pending in Korea
  • 3 applications pending in China
  • 1 application pending in Canada
  • 1 application pending in India
Pending 8 Licensed Patent Applications
  • 5 applications pending in the US
  • 3 applications pending at the World IP Organization (under the PCT)